Integral Health Asset Management, LLC Revance Therapeutics, Inc. Transaction History

Integral Health Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $1.17 Million - $2.37 Million	500,000 New	500,000 $1.29 Million
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $2.03 Million - $3.92 Million	350,000 Added 350.0%	450,000 $3.96 Million
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $1.72 Million - $3.76 Million	-150,000 Reduced 60.0%	100,000 $1.15 Million
Q1 2023 May 09, 2023	BUY	$18.36 - $35.27 $183,600 - $352,700	10,000 Added 4.17%	250,000 $8.05 Million
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $1.65 Million - $2.76 Million	90,000 Added 60.0%	240,000 $4.43 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $2.15 Million - $4.27 Million	150,000 New	150,000 $4.05 Million
Q4 2021 Feb 02, 2022	SELL	$12.46 - $27.87 $623,000 - $1.39 Million	-50,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $1.29 Million - $1.66 Million	50,000 New	50,000 $1.39 Million

102

44.7M

2.05M

5.47M

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.